Natera presents 35 oncology studies at ASCO annual meeting

Natera, Inc.

Natera, Inc.

NTRA

0.00
  • Natera will present 35 oncology studies at the American Society of Clinical Oncology Annual Meeting, held May 29-June 2 in Chicago.
  • Program includes three oral presentations, with data centered on its Signatera molecular residual disease test across colorectal cancer, lung cancer, lymphoma, breast cancer.
  • Key readouts highlighted include a pooled real-world analysis linking Signatera positivity to higher recurrence or death risk in the adjuvant window (HR 8.15) and higher recurrence risk in surveillance (HR 18.3).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.